[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626731":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":20,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","Vonoprazan 20mg twice a day + clarithromycin 500mg twice a day",[13],"Drug: Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days","Participants receive vonoprazan 20 mg orally twice daily plus clarithromycin 500 mg orally twice daily for 14 consecutive days.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Weihong Wang, MD, PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","13041171610","wangweihong2581@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Meng Li","18612034366","dr_limeng@163.com",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"type":24,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Weihong Wang","Professor","100626731","simplified-dual-regimen-guided-by-fecal-clarithromycin-resistance-gene-detection-for-first-line-h-pylori-eradication-100626731",false,"NCT07439445","Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication","Efficacy and Safety of Simplified Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line Helicobacter Pylori Eradication","Inclusion Criteria:\n\n1. Aged 18-70 years;\n2. Positive results for both ¹³C-urea breath test (¹³C-UBT) and fecal polymerase chain reaction (PCR), confirming Helicobacter pylori infection, with a clinical indication for H. pylori eradication as judged by the physician;\n3. Treatment-naïve individuals with no prior history of H. pylori eradication therapy.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Patients with a history of allergy to any drugs used in the eradication regimen\n3. Patients with severe systemic diseases or malignant tumors\n4. History of gastric resection surgery\n5. Recent use of antibiotics or bismuth salts (within 4 weeks), H₂-receptor antagonists, proton pump inhibitors (PPIs), or Potassium-competitive acid blockers(P-CABs) (within 2 weeks).","ALL","18 Years","70 Years",{"count":64,"type":65},70,"ESTIMATED","INTERVENTIONAL",[68],"NA","To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.",[71],"Helicobacter Pylori Infection","2026-04-25",{"date":74,"type":75},"2026-04-30","ACTUAL",{"date":72,"type":75},{"date":78,"type":65},"2027-02-13",{"name":5,"class":6},1]